The first month of 2016 brought only 18 M&A deals, but among them was a major acquisition announcement that could have significant impact on the rapidly evolving in-vitro diagnostics space.
On Jan. 8, Thermo Fisher Scientific announced an agreement to acquire Affymetrix for $14.00 per share in cash, nearly $1.3bn in total, representing a 52% premium over Affymetrix's share price when the deal was announced